FDA Grants Orphan Drug Designation to Elixirgen’s Gene Therapy for Rare Disease

Elixirgen Therapeutics, a clinical-stage biotech company focused on rare diseases, has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its gene therapy, EXG-34217. The therapy, designed to treat Telomere Biology Disorders (TBDs) with bone marrow failure, is currently being evaluated in an ongoing Phase 1/2 trial. This designation offers Elixirgen financial and regulatory incentives, including tax credits, grants, and a potential seven years of market exclusivity if EXG-34217 is approved.

In addition to Orphan Drug Designation, EXG-34217 was recently awarded Rare Pediatric Disease and Regenerative Medicine Advanced Therapy (RMAT) designations. These recognitions highlight the therapy’s potential to address the urgent unmet needs of patients suffering from TBDs. Enrollment for the trial remains open to participants aged 12 and older, as the company continues its mission to develop innovative treatments for rare and life-threatening conditions.